7 results on '"Frerix, Marc"'
Search Results
2. Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study
- Author
-
Valentini, Gabriele, Huscher, Dörte, Riccardi, Antonella, Fasano, Serena, Irace, Rosaria, Messiniti, Valentina, Matucci-Cerinic, Marco, Guiducci, Serena, Distler, Oliver, Maurer, Britta, Avouac, Jérôme, Tarner, Ingo H, Frerix, Marc, Riemekasten, Gabriela, Siegert, Elise, Czirják, László, Lóránd, Veronika, Denton, Christopher P, Nihtyanova, Svetlana, Walker, Ulrich A, Jaeger, Veronika K, Del Galdo, Francesco, Abignano, Giuseppina, Ananieva, Lidia P, Gherghe, Ana Maria, Mihai, Carina, Henes, Joerg Christoph, Schmeiser, Tim, Vacca, Alessandra, Moiseev, Sergey, et al, University of Zurich, and Valentini, Gabriele
- Subjects
2403 Immunology ,1300 General Biochemistry, Genetics and Molecular Biology ,2745 Rheumatology ,10051 Rheumatology Clinic and Institute of Physical Medicine ,2723 Immunology and Allergy ,610 Medicine & health - Published
- 2019
3. Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey
- Author
-
Blagojevic, Jelena, Bellando-Randone, Silvia, Abignano, Giuseppina, Avouac, Jérôme, Cometi, L, Czirják, László, Denton, Christopher P, Distler, Oliver, Frerix, Marc, Guiducci, Serena, Huscher, Dörte, Jaeger, Veronika K, Lóránd, Veronika, Maurer, Britta, Nihtyanova, Svetlana, Riemekasten, Gabriela, Siegert, Elise, Tarner, Ingo H, Vettori, Serena, Walker, Ulrich A, Allanore, Yannick, Müller-Ladner, Ulf, Del Galdo, Francesco, Matucci-Cerinic, Marco, EUSTAR co-workers, University of Zurich, Blagojevic, Jelena, Blagojevic, J., Bellando-Randone, S., Abignano, G., Avouac, J., Cometi, L., Czirják, L., Denton, C. P., Distler, O., Frerix, M., Guiducci, S., Huscher, D., Jaeger, V. K., Lóránd, V., Maurer, B., Nihtyanova, S., Riemekasten, G., Siegert, E., Tarner, I. H., Vettori, S., Walker, U. A., Allanore, Y., Müller-Ladner, U., Del Galdo, F., and Matucci-Cerinic, M.
- Subjects
0301 basic medicine ,Male ,lcsh:Diseases of the musculoskeletal system ,Observational Trial ,2745 Rheumatology ,Digital ulcer ,Categorisation ,Scleroderma ,Systemic sclerosi ,0302 clinical medicine ,Surveys and Questionnaires ,Immunology and Allergy ,Prospective Studies ,10051 Rheumatology Clinic and Institute of Physical Medicine ,Digital ulcers ,Middle Aged ,Calcium Channel Blockers ,Classification ,3. Good health ,Clinical Practice ,Categorization ,2723 Immunology and Allergy ,Systemic sclerosis ,Drug Therapy, Combination ,Female ,Research Article ,Adult ,medicine.medical_specialty ,Immunology ,610 Medicine & health ,Sildenafil Citrate ,Fingers ,03 medical and health sciences ,Rheumatology ,Skin Ulcer ,medicine ,Humans ,In patient ,European Union ,Iloprost ,030203 arthritis & rheumatology ,2403 Immunology ,Scleroderma, Systemic ,business.industry ,Bosentan ,Essential item ,medicine.disease ,030104 developmental biology ,Essential items ,Physical therapy ,Observational study ,lcsh:RC925-935 ,business - Abstract
Background: A consensus on digital ulcer (DU) definition in systemic sclerosis (SSc) has been recently reached (Suliman et al., J Scleroderma Relat Disord 2:115-20, 2017), while for their evaluation, classification and categorisation, it is still missing. The aims of this study were to identify a set of essential items for digital ulcer (DU) evaluation, to assess if the existing DU classification was useful and feasible in clinical practice and to investigate if the new categorisation was preferred to the simple distinction of DU in recurrent and not recurrent, in patients with systemic sclerosis (SSc).Methods: DeSScipher is the largest European multicentre study on SSc. It consists of five observational trials (OTs), and one of them, OT1, is focused on DU management. The DeSScipher OT1 items on DU that reached ≥ 60% of completion rate were administered to EUSTAR (European Scleroderma Trials and Research group) centres via online survey. Questions about feasibility and usefulness of the existing DU classification (DU due to digital pitting scars, to loss of tissue, derived from calcinosis and gangrene) and newly proposed categorisation (episodic, recurrent and chronic) were also asked.Results: A total of 84/148 (56.8%) EUSTAR centres completed the questionnaire. DeSScipher items scored by ≥ 70% of the participants as essential and feasible for DU evaluation were the number of DU defined as a loss of tissue (level of agreement 92%), recurrent DU (84%) and number of new DU (74%). For 65% of the centres, the proposed classification of DU was considered useful and feasible in clinical practice. Moreover, 80% of the centres preferred the categorisation of DU in episodic, recurrent and chronic to simple distinction in recurrent/not recurrent DU.Conclusions: For clinical practice, EUSTAR centres identified only three essential items for DU evaluation and considered the proposed classification and categorisation as useful and feasible. The set of items needs to be validated while further implementation of DU classification and categorisation is warranted.Trial registration: Observational trial on DU (OT1) is one of the five trials of the DeSScipher project (ClinicalTrials.gov; OT1 Identifier: NCT01836263, posted on April 19, 2013).
- Published
- 2018
4. Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group
- Author
-
Jaeger, Veronika K, Distler, Oliver, Maurer, Britta, Czirják, László, Lóránd, Veronika, Valentini, Gabriele, Vettori, Serena, Del Galdo, Francesco, Abignano, Giuseppina, Denton, Christopher P, Nihtyanova, Svetlana, Allanore, Yannick, Avouac, Jérôme, Riemekasten, Gabriele, Siegert, Elise, Huscher, Dörte, Matucci-Cerinic, Marco, Guiducci, Serena, Frerix, Marc, Tarner, Ingo H, Garay Toth, Beata, Fankhauser, Beat, Umbricht, Jörg, Zakharova, Anastasia, Mihai, Carina, Cozzi, Franco, Yavuz, Sule, Hunzelmann, Nicolas, Rednic, Simona, Vacca, Alessandra, et al, and University of Zurich
- Subjects
2745 Rheumatology ,10051 Rheumatology Clinic and Institute of Physical Medicine ,2736 Pharmacology (medical) ,610 Medicine & health - Published
- 2018
5. Update of EULAR recommendations for the treatment of systemic sclerosis
- Author
-
Kowal-Bielecka, Otylia, Fransen, Jaap, Avouac, Jerome, Becker, Mike, Kulak, Agnieszka, Allanore, Yannick, Distler, Oliver, Clements, Philip, Cutolo, Maurizio, Czirjak, Laszlo, Damjanov, Nemanja, Del Galdo, Francesco, Denton, Christopher P, Distler, Jörg H W, Foeldvari, Ivan, Figelstone, Kim, Frerix, Marc, Furst, Daniel E, Guiducci, Serena, Hunzelmann, Nicolas, Khanna, Dinesh, Matucci-Cerinic, Marco, Herrick, Ariane L, van den Hoogen, Frank, van Laar, Jacob M, Riemekasten, Gabriela, Silver, Richard, Smith, Vanessa, Sulli, Alberto, Tarner, Ingo, et al, University of Zurich, and Kowal-Bielecka, Otylia
- Subjects
2403 Immunology ,1300 General Biochemistry, Genetics and Molecular Biology ,2745 Rheumatology ,10051 Rheumatology Clinic and Institute of Physical Medicine ,2723 Immunology and Allergy ,610 Medicine & health - Published
- 2017
6. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
- Author
-
Christopher P. Denton, Francesco DelGaldo, László Czirják, Gabriele Valentini, Elise Siegert, Sabine Adler, Peter M. Villiger, Marco Matucci-Cerinic, Dörte Huscher, Ulrich A Walker, Yannick Allanore, Marc Frerix, Ulf Mueller-Ladner, Ingo-Helmut Tarner, Oliver Distler, Gabriela Riemekasten, Adler, Sabine, Huscher, Dã¶rte, Siegert, Elise, Allanore, Yannick, Czirjã¡k, Lã¡szlã³, Delgaldo, Francesco, Denton, Christopher P., Distler, Oliver, Frerix, Marc, Matucci-Cerinic, Marco, Mueller-Ladner, Ulf, Tarner, Ingo-Helmut, Valentini, Gabriele, Walker, Ulrich A., Villiger, Peter M., Riemekasten, Gabriela, and University of Zurich
- Subjects
Male ,Vital capacity ,lcsh:Diseases of the musculoskeletal system ,2745 Rheumatology ,Azathioprine ,Pulmonary function testing ,Systemic sclerosi ,0302 clinical medicine ,DLCO ,Diffusing capacity ,Immunology and Allergy ,Precision Medicine ,skin and connective tissue diseases ,Lung ,Immunosuppressant ,Interstitial lung disease ,10051 Rheumatology Clinic and Institute of Physical Medicine ,respiratory system ,Middle Aged ,3. Good health ,Respiratory Function Tests ,2723 Immunology and Allergy ,Systemic sclerosis ,Drug Therapy, Combination ,Female ,Immunosuppressive Agents ,medicine.drug ,Research Article ,Adult ,medicine.medical_specialty ,Immunology ,610 Medicine & health ,03 medical and health sciences ,FEV1/FVC ratio ,Rheumatology ,Internal medicine ,medicine ,Humans ,Cyclophosphamide ,Aged ,030203 arthritis & rheumatology ,2403 Immunology ,Scleroderma, Systemic ,business.industry ,Follow up ,Mycophenolic Acid ,medicine.disease ,Lung function ,respiratory tract diseases ,Immunosuppressants ,Methotrexate ,030228 respiratory system ,lcsh:RC925-935 ,business ,Lung Diseases, Interstitial ,Rheumatism - Abstract
Background Interstitial lung disease in systemic sclerosis (SSc-ILD) is a major cause of SSc-related death. Imunosuppressive treatment (IS) is used in patients with SSc for various organ manifestations mainly to ameliorate progression of SSc-ILD. Data on everyday IS prescription patterns and clinical courses of lung function during and after therapy are scarce. Methods We analysed patients fulfilling American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) 2013 criteria for SSc-ILD and at least one report of IS. Types of IS, pulmonary function tests (PFT) and PFT courses during IS treatment were evaluated. Results EUSTAR contains 3778/11,496 patients with SSc-ILD (33%), with IS in 2681/3,778 (71%). Glucocorticoid (GC) monotherapy was prescribed in 30.6% patients with GC combinations plus cyclophosphamide (CYC) (11.9%), azathioprine (AZA) (9.2%), methotrexate (MTX) (8.7%), or mycophenolate mofetil (MMF) (7.3%). Intensive IS (MMF + GC, CYC or CYC + GC) was started in patients with the worst PFTs and ground glass opacifications on imaging. Patients without IS showed slightly less worsening in forced vital capacity (FVC) when starting with FVC 50–75% or >75%. GC showed negative trends when starting with FVC
- Published
- 2017
7. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index
- Author
-
Ulrich A Walker, Oliver Distler, Suzana Jordan, Gabriele Valentini, Otylia Kowal-Bielecka, Serena Vettori, Gabriela Riemekasten, Elise Siegert, Murray Baron, Voon H Ong, Michele Iudici, Jérôme Avouac, Janet E. Pope, Yannick Allanore, Veronika K. Jaeger, Marc Frerix, Eric Hachulla, Ariane L. Herrick, László Czirják, Ulf Müller-Ladner, Tünde Minier, Patricia Carreira, Christopher P. Denton, Valentini, Gabriele, Iudici, Michele, Walker, Ulrich A., Jaeger, Veronika K., Baron, Murray, Carreira, Patricia, Czirják, László, Denton, Christopher P., Distler, Oliver, Hachulla, Eric, Herrick, Ariane L., Kowal Bielecka, Otylia, Pope, Janet, Müller Ladner, Ulf, Riemekasten, Gabriela, Avouac, Jerome, Frerix, Marc, Jordan, Suzana, Minier, Tünde, Siegert, Elise, Ong, Voon H., Vettori, Serena, Allanore, Yannick, and University of Zurich
- Subjects
0301 basic medicine ,Male ,2745 Rheumatology ,Activity index ,Severity of Illness Index ,Scleroderma ,0302 clinical medicine ,DLCO ,Diffusing capacity ,Medicine and Health Sciences ,Medicine ,Immunology and Allergy ,Aged, 80 and over ,Medicine (all) ,10051 Rheumatology Clinic and Institute of Physical Medicine ,Middle Aged ,Europe ,2723 Immunology and Allergy ,Female ,Adult ,medicine.medical_specialty ,Immunology ,610 Medicine & health ,Sensitivity and Specificity ,Autoimmune Disease ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Young Adult ,Rheumatology ,1300 General Biochemistry, Genetics and Molecular Biology ,Internal medicine ,Linear regression ,Humans ,Derivation ,Disease Activity ,Aged ,Systemic Sclerosi ,030203 arthritis & rheumatology ,2403 Immunology ,Scleroderma, Systemic ,Biochemistry, Genetics and Molecular Biology (all) ,business.industry ,Reproducibility of Results ,Gold standard (test) ,medicine.disease ,030104 developmental biology ,ROC Curve ,Physical therapy ,Observational study ,business ,Follow-Up Studies - Abstract
BackgroundValidity of European Scleroderma Study Group (EScSG) activity indexes currently used to assess disease activity in systemic sclerosis (SSc) has been criticised.MethodsThree investigators assigned an activity score on a 0–10 scale for 97 clinical charts. The median score served as gold standard. Two other investigators labelled the disease as inactive/moderately active or active/very active. Univariate–multivariate linear regression analyses were used to define variables predicting the ‘gold standard’, their weight and derive an activity index. The cut-off point of the index best separating active/very active from inactive/moderately active disease was identified by a receiver-operating curve analysis. The index was validated on a second set of 60 charts assessed by three different investigators on a 0–10 scale and defined as inactive/moderately active or active/very active by other two investigators. One hundred and twenty-three were investigated for changes over time in the index and their relationships with those in the summed Medsger severity score (MSS).ResultsA weighted 10-point activity index was identified and validated: Δ-skin=1.5 (Δ=patient assessed worsening during the previous month), modified Rodnan skin score (mRss) >18=1.5, digital ulcers=1.5, tendon friction rubs=2.25, C-reactive protein >1 mg/dL=2.25 and diffusing capacity of the lung for CO (DLCO) % predicted ConclusionsA preliminarily revised SSc activity index has been developed and validated, providing a valuable tool for clinical practice and observational studies.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.